Piper Sandler lowered the firm’s price target on Adaptive Biotechnologies to $13 from $14 and keeps an Overweight rating on the shares. The firm is updating its 2024 and 2025 revenues for all of its life science tools and labs coverage to account for lower expected spending on capital equipment and pharma services due to economic factors, including access to capital by companies and their customers and lower appetite for spending from pharma. Piper is also lowering its 2023 revenues for Fx.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on ADPT:
- Biotech Alert: Searches spiking for these stocks today
- Adaptive Biotechnologies announces launch of Epic Integration for clonoSEQ
- Adaptive Announces Launch of Epic Integration for clonoSEQ®
- Adaptive Biotechnologies to Participate in the Morgan Stanley 21st Annual Global Healthcare Conference
- Cathie Wood’s ARK Investment bought 176.1K shares of Adaptive Biotechnologies